retatrutide phase 2 trial new england journal of medicine 2023年度回顧】 NEJM Notable Articles 2023 Day 3: Triple–Hormone-Receptor Agonist for Obesity — A Trial. N Engl J Med 2023; 389:514-526. 製圖：Sardinosis Retatrutide: What It Is &

Nixon and Rubinsztein, 2024)

Its multi-pathway design helps maintain steady energy levels and metabolic balance avoiding the energy crashes that can accompany aggressive caloric restriction

Approved GLP-1 Claims by Product Data Source: IRIS by Real Chemistry & Google Trends | Image Credit: Real Chemistry The first GLP-1 receptor agonist approved for obesity was liraglutide, marketed in the U.S

Additionally, many patients appreciate the positive side effects, such as weight loss, rather than severe drawbacks associated with some diabetes medications

Reclaiming Your Metabolic Health through Specialist Care The evolution of metabolic treatment has reached a pivotal moment with the introduction of dual-agonist therapies